168
Participants
Start Date
August 18, 2021
Primary Completion Date
January 15, 2025
Study Completion Date
July 31, 2029
MB-CART2019.1
MB-CART2019.1 is designed to effectively target malignant B cells in patients suffering from late stage haematological B-cell malignancies. MB-CART2019.1 consists of autologous cluster of differentiation CD20/CD19 chimeric antigen receptor (CAR) transduced CD4/CD8 enriched T cells, derived from a leukapheresis and processed by using the CliniMACS Prodigy® device.
R-GemOx or BR plus polatuzumab vedotin
Immunochemotherapy will be administered as per arm description.
Jules Bordet lnstitute, Anderlecht
Medizinische Universitaet Wien - Allgemeines Krankenhaus der Stadt Wien (AKH), Vienna
Del-Pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet, Budapest
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven
Ordensklinikum Linz GmbH Elisabethinen, Linz
Debreceni Egyetem - Orvos es Egeszsegtudomanyi Centrum (DEOEC) (University of Debrecen Medical and Health Science Center), Debrecen
Universite Catholique de Louvain Namur, Centre Hospitalier Universitaire Dinant Godinne Site Godinne, Yvoir
Universitatsklinikum Innsbruck Universitatsklinik fur Innere Medizin V, Innsbruck
Medizinische Universitaetsklinik Graz, Graz
Azienda Ospedaliera San Giovanni Battista Di Torino, Torino
Helios Klinikum Berlin - Buch, Berlin
Centre Paoli Calmettes, Marseille
Asklepios Klinik St. Georg, Hamburg
University Medical Center Hamburg-Eppendorf, Hamburg
Hospital Universitario Fundacion Jimenez Diaz, Madrid
Hospital Universitario Virgen De La Arrixaca (Huva), Murcia
Clinica Universidad de Navarra, Pamplona
Institut Universitaire du Cancer Service d´hématologie, Toulouse
Centre Hospitalier Universitaire de Bordeaux - Hopital Haut-Leveque, Pessac
Centre Hospitalier Universitaire de Montpellier - Hopital Saint-Eloi, Montpellier
CHU de Rennes - Hopital de Pontchaillou, Rennes
Hospital Clinico Universitario de Salamanca, Salamanca
Hospital Universitario Virgen del Rocio, Seville
Centre Hospitalier Universitaire de Nantes (CHU de Nantes) - Hopital Hotel Dieu, Nantes
Universitaetsklinikum Knappschaftskrankenhaus Bochum der Ruhr-Universitat Bochum, Bochum
Universitaetsklinikum Essen, Essen
Universitaetsklinikum Muenster, Münster
University Hospital Hradec Kralove, Hradec Králové
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu. Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku, Wroclaw
Universitaetsklinikum Koeln, Cologne
CHU de Nancy Hopitaux de Brabois, Vandœuvre-lès-Nancy
CHRU de Lille - Hopital Claude Huriez, Lille
Universitaetsklinikum Heidelberg, Heidelberg
Centre Hospitalier Lyon Sud, Hospices Civils de Lyon Groupement Hospitalier Sud, Lyon
FNsP Ostrava, Ostrava
University Hospital of Tuebingen, Tübingen
Hospital Saint-Louis - APHP, Paris
Klinikum der Universitat München, Studienzentrale fur Hematologie der Medizinischen Klinik II, München
Centre Hospitalier Universitaire de Poitiers, Poitiers
Universitatsklinikum Augsburg, Augsburg
Klinikum Erlangen der Friedrich-Alexander-Universitaet Erlangen-Nuernberg, Erlangen
University Hospital Regensburg, Regensburg
Centre Hospitalier Universitaire (CHU) - Hopital Henri Mondor, Créteil
Universitätsklinikum Leipzig, Leipzig
VUH Santaros Klinikos, Vilnius
Amsterdam Universitaire Medische Centra (UMC) - locatie Amsterdam Medisch Centrum (AMC), Amsterdam
University Medical Center Groningen, Groningen
Leiden University Medical Center (LUMC), Leiden
Erasmus University Medical Center, Rotterdam
Hospital Universitari Vall d'Hebron, Barcelona
Hospital Clinic de Barcelona (Hospital Clinic i Provincial), Barcelona
Catalan Institute of Oncology (ICO) Hospitalet, Barcelona
Onkologikliniken, Uppsala
Lead Sponsor
Collaborators (1)
ICON plc
INDUSTRY
Miltenyi Biomedicine GmbH
INDUSTRY